Literature DB >> 25767185

Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation.

A P Nayate1, J G Dubroff1, J E Schmitt1, I Nasrallah1, R Kishore1, D Mankoff1, D A Pryma2.   

Abstract

BACKGROUND AND
PURPOSE: Fluorine-18 florbetapir is a recently developed β-amyloid plaque positron-emission tomography imaging agent with high sensitivity, specificity, and accuracy in the detection of moderate-to-frequent cerebral cortical β-amyloid plaque. However, the FDA has expressed concerns about the consistency of interpretation of [(18)F] florbetapir PET brain scans. We hypothesized that incorporating automated cerebral-to-whole-cerebellar standardized uptake value ratios into [(18)F] florbetapir PET brain scan interpretation would reduce this interreader variability.
MATERIALS AND METHODS: This randomized, blinded-reader study used previously acquired [(18)F] florbetapir scans from 30 anonymized patients who were enrolled in the Alzheimer's Disease Neuroimaging Initiative 2. In 4 separate, blinded-reading sessions, 5 readers classified 30 cases as positive or negative for significant β-amyloid deposition either qualitatively alone or qualitatively with additional adjunct software that determined standardized uptake value ratios. A κ coefficient was used to calculate interreader agreement with and without the use of standardized uptake value ratios.
RESULTS: There was complete interreader agreement on 20/30 cases of [(18)F] florbetapir PET brain scans by using qualitative interpretation and on 27/30 scans interpreted with the adjunct use of standardized uptake value ratios. The κ coefficient for the studies read with standardized uptake value ratios (0.92) was significantly higher compared with the qualitatively read studies (0.69, P = .006).
CONCLUSIONS: Use of standardized uptake value ratios improves interreader agreement in the interpretation of [(18)F] florbetapir images.
© 2015 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25767185      PMCID: PMC7965291          DOI: 10.3174/ajnr.A4281

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  38 in total

1.  FDA approves 18F-florbetapir PET agent.

Authors: 
Journal:  J Nucl Med       Date:  2012-06       Impact factor: 10.057

2.  In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).

Authors:  Dean F Wong; Paul B Rosenberg; Yun Zhou; Anil Kumar; Vanessa Raymont; Hayden T Ravert; Robert F Dannals; Ayon Nandi; James R Brasić; Weiguo Ye; John Hilton; Constantine Lyketsos; Hank F Kung; Abhinay D Joshi; Daniel M Skovronsky; Michael J Pontecorvo
Journal:  J Nucl Med       Date:  2010-06       Impact factor: 10.057

3.  Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease.

Authors:  Steven Ng; Victor L Villemagne; Sam Berlangieri; Sze-Ting Lee; Martin Cherk; Sylvia J Gong; Uwe Ackermann; Tim Saunder; Henri Tochon-Danguy; Gareth Jones; Clare Smith; Graeme O'Keefe; Colin L Masters; Christopher C Rowe
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

4.  Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.

Authors:  Henryk Barthel; Julia Luthardt; Georg Becker; Marianne Patt; Eva Hammerstein; Kristin Hartwig; Birk Eggers; Bernhard Sattler; Andreas Schildan; Swen Hesse; Philipp M Meyer; Henrike Wolf; Torsten Zimmermann; Joachim Reischl; Beate Rohde; Hermann-Josef Gertz; Cornelia Reininger; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-06       Impact factor: 9.236

5.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

Authors:  Christopher M Clark; Michael J Pontecorvo; Thomas G Beach; Barry J Bedell; R Edward Coleman; P Murali Doraiswamy; Adam S Fleisher; Eric M Reiman; Marwan N Sabbagh; Carl H Sadowsky; Julie A Schneider; Anupa Arora; Alan P Carpenter; Matthew L Flitter; Abhinay D Joshi; Michael J Krautkramer; Ming Lu; Mark A Mintun; Daniel M Skovronsky
Journal:  Lancet Neurol       Date:  2012-06-28       Impact factor: 44.182

Review 6.  Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.

Authors:  Keith A Johnson; Satoshi Minoshima; Nicolaas I Bohnen; Kevin J Donohoe; Norman L Foster; Peter Herscovitch; Jason H Karlawish; Christopher C Rowe; Maria C Carrillo; Dean M Hartley; Saima Hedrick; Virginia Pappas; William H Thies
Journal:  J Nucl Med       Date:  2013-01-28       Impact factor: 10.057

7.  Differentiation of pleural effusions from parenchymal opacities: accuracy of bedside chest radiography.

Authors:  Mary T Kitazono; Charles T Lau; Andrea N Parada; Pooja Renjen; Wallace T Miller
Journal:  AJR Am J Roentgenol       Date:  2010-02       Impact factor: 3.959

8.  Alzheimer's disease with and without coexisting Parkinson's disease changes: apolipoprotein E genotype and neuropathologic correlates.

Authors:  M Gearing; J A Schneider; G W Rebeck; B T Hyman; S S Mirra
Journal:  Neurology       Date:  1995-11       Impact factor: 9.910

9.  Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.

Authors:  V Camus; P Payoux; L Barré; B Desgranges; T Voisin; C Tauber; R La Joie; M Tafani; C Hommet; G Chételat; K Mondon; V de La Sayette; J P Cottier; E Beaufils; M J Ribeiro; V Gissot; E Vierron; J Vercouillie; B Vellas; F Eustache; D Guilloteau
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-18       Impact factor: 9.236

10.  Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.

Authors:  P M Doraiswamy; R A Sperling; K Johnson; E M Reiman; T Z Wong; M N Sabbagh; C H Sadowsky; A S Fleisher; A Carpenter; A D Joshi; M Lu; M Grundman; M A Mintun; D M Skovronsky; M J Pontecorvo
Journal:  Mol Psychiatry       Date:  2014-03-11       Impact factor: 15.992

View more
  18 in total

1.  Establishing Amyloid PET Imaging Biomarkers: Ongoing Efforts.

Authors:  S Minoshima
Journal:  AJNR Am J Neuroradiol       Date:  2015-05-21       Impact factor: 3.825

2.  Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging.

Authors:  Michael J Pontecorvo; Anupa K Arora; Marybeth Devine; Ming Lu; Nick Galante; Andrew Siderowf; Catherine Devadanam; Abhinay D Joshi; Stephen L Heun; Brian F Teske; Stephen P Truocchio; Michael Krautkramer; Michael D Devous; Mark A Mintun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-07       Impact factor: 9.236

3.  Yes we can analyse amyloid images - Now What?

Authors:  Henryk Barthel; John Seibyl; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05       Impact factor: 9.236

4.  Validation of a spatial normalization method using a principal component derived adaptive template for [18F]florbetaben PET.

Authors:  Antoine Leuzy; Kerstin Heurling; Susan De Santi; Santiago Bullich; Oskar Hansson; Johan Lilja
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-08-25

Review 5.  Amyloid Imaging: Poised for Integration into Medical Practice.

Authors:  Keshav Anand; Marwan Sabbagh
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

6.  Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) multicenter study.

Authors:  Tomohiko Yamane; Kenji Ishii; Muneyuki Sakata; Yasuhiko Ikari; Tomoyuki Nishio; Kazunari Ishii; Takashi Kato; Kengo Ito; Michio Senda
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-13       Impact factor: 9.236

7.  Augmenting Amyloid PET Interpretations With Quantitative Information Improves Consistency of Early Amyloid Detection.

Authors:  Nicholas R Harn; Suzanne L Hunt; Jacqueline Hill; Eric Vidoni; Mark Perry; Jeffrey M Burns
Journal:  Clin Nucl Med       Date:  2017-08       Impact factor: 7.794

8.  Optimisation and usefulness of quantitative analysis of 18F-florbetapir PET.

Authors:  Daniel Fakhry-Darian; Neva Hiten Patel; Sairah Khan; Tara Barwick; William Svensson; Sameer Khan; Richard J Perry; Paresh Malhotra; Christopher J Carswell; Kuldip S Nijran; Zarni Win
Journal:  Br J Radiol       Date:  2019-05-14       Impact factor: 3.039

9.  Visual interpretation of [18F]Florbetaben PET supported by deep learning-based estimation of amyloid burden.

Authors:  Ji-Young Kim; Dongkyu Oh; Kiyoung Sung; Hongyoon Choi; Jin Chul Paeng; Gi Jeong Cheon; Keon Wook Kang; Dong Young Lee; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-09-29       Impact factor: 9.236

10.  A 4-Year Follow-Up of Subjects with Visually Equivocal Amyloid Positron Emission Tomography Findings from the Alzheimer's Disease Neuroimaging Initiative Cohort.

Authors:  Minyoung Oh; Minjung Seo; Sun Young Oh; Heeyoung Kim; Byung Wook Choi; Jungsu S Oh; Jae Seung Kim
Journal:  Nucl Med Mol Imaging       Date:  2021-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.